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The treatment of chronic myeloid leukaemia (CML) has rapidly evolved since the invent of tyrosine 
kinase inhibitor (TKI) therapy. The efficacy of the first TKI, imatinib, was initially evaluated in the 
IRIS trial (started in June 2000) and shown to be superior to previous treatments.1 Up to now, 
there is almost 20 years of experience of TKI therapy, and the current life expectancy of CML 
patients treated with TKI therapy equals age-matched healthy controls. Initially, genetic and 
molecular responses and the prevention of accelerated phase of CML with TKI therapy were 
important treatment goals. These goals are still valid, but currently when patient is diagnosed with 
chronic phase CML, many times the treating physician already discusses the possibility of 
treatment free remission in the future. During the last 10 years many treatment discontinuation 
trials have been performed, and they have evaluated the safety and efficacy of TKI discontinuation 
in CML patients who have achieved deep molecular remission (at least molecular remission 4, 
MR4). The long-term follow-up of the first larger STIM1 trial showed that with the median follow-
up of more than 6 years, 43% of patients were still in remission after TKI discontinuation.2 The 
EURO-SKI trial included over 700 patients and showed that at 24 months after TKI stopping the 
molecular relapse-free survival was 50%.3 Based on these positive results, some of the current 
clinical guidelines already state that TKI discontinuation can be considered in selected patients 
outside the clinical trials.4 Prerequisites for safe TKI discontinuation have been suggested: chronic 
phase of the disease, at least 3-5 years of prior TKI therapy, quantifiable BCR-ABL1 transcript, 
access to high quality monitoring, and stable molecular response (BCR-ABL1 ≤0.01% IS for more 
than 2 years). 
 
In the Lancet Haematology, Clark and colleagues report the final results of the DESTINY trial 
evaluating the feasibility of TKI de-escalation before stopping, and its impact on the molecular 
relapse rates.5 In addition, they include a previously mostly unstudied patient cohort, patients in 
major molecular remission MMR but not in stable MR4, to their clinical trial. Compared to other 
published TKI discontinuation studies these are both novel aspects since in previous studies TKI 
therapy have been stopped abruptly without de-escalation. It has even been considered that de-
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escalation is not recommendable since it may allow the expansion of existing leukaemia cells and 
putative TKI resistant clones. The interim report of DESTINY trial published in 20176 showed that 
the de-escalation to half of the standard dose of therapy is safe and results to molecular relapse 
only in a minor fraction of patients (7% within 12 months of half-dose therapy). In the current final 
analysis of the study (12 months de-escalation followed by the TKI stop) they show that 36-month 
recurrent free survival is notably high, 72%, in the MR4 cohort (n=125). In the MMR cohort (n=49), 
this is clearly lower (36%), but it should be noted that still one third of the patients stay in 
remission after the TKI stop. Furthermore, sub-analysis suggests that one single PCR result at the 
trial entry is not optimal as it would have classified the majority of MMR patients to wrong MR4 
cohort with different outcome.  
As the rate of treatment free remission in the DESTINY trial is superior to previous studies, it raises 
the question what is the cause for this? Multivariate analysis of clinical factors only showed that 
the trial group (MR4 versus MMR) and the duration of TKI treatment predicted molecular 
recurrence. The predictive value of treatment duration has also been shown in previous studies, 
such as in the EURO-SKI study.3 However, this cannot explain the difference in remission rates 
since the median duration of treatment in the DESTINY trial (6.9 years) does not differ from other 
trials. The authors speculate that TKI de-escalation may allow leukaemia stem cells to leave their 
quiescent state, and this may dispose them better to the effect of TKI treatment. Furthermore, the 
de-escalation phase may create an optimal window for immune system to respond and react to 
proliferating leukaemia cells. The importance of immune system has also been shown in 
conjunction with other stopping trials.7-9 The more detailed biological understanding of the 
importance of both of these factors (leukaemia stem cells and immune system) in successful TKI 
discontinuation is highly warranted, and this study will hopefully create possibility for that in the 
future with advanced single cell sequencing techniques and available bone marrow samples 
collected during the trial. 
But how to now translate these results to clinical practice? Should it be added to the guidelines 
that de-escalation is recommended instead of rapid TKI stop? As the treatment free remission rate 
with de-escalation is similar with the other trial using one-year maintenance therapy with 
interferon before total treatment discontinuation10 it could also be asked are these same patients 
that benefit from both approaches or different patients? TKI stopping biology may be highly 
variable between individual patients, and “one size fits all” ideology would not be ideal here. All in 
all, this suggests that randomized TKI stopping trials with different treatment discontinuation 
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approaches should be performed in order to define the optimal stopping guidelines. These should 
be accompanied with translational studies and unified registries allowing meta-analysis before 
definite clinical guidelines advising optimal treatment discontinuation strategy can be set. 
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